Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates

Ronald G. Lafrenière(Xenon Pharmaceuticals (Canada)), Mark Samuels(Xenon Pharmaceuticals (Canada)), Marcia L.E. MacDonald(Xenon Pharmaceuticals (Canada)), Marie‐Pierre Dubé(Montreal Heart Institute), Owen Dadivas(Xenon Pharmaceuticals (Canada)), Jay Thompson(Xenon Pharmaceuticals (Canada)), Bernard Brais(Montreal Neurological Institute and Hospital), Gudarz Davar(Brigham and Women's Hospital), Ryan R. Brinkman(BC Cancer Agency), Michael R. Hayden(University of British Columbia), Christèle Platon(Xenon Pharmaceuticals (Canada)), Xandra O. Breakefield(Harvard University), Julie MacFarlane(Xenon Pharmaceuticals (Canada)), Terry D. Pape(Xenon Pharmaceuticals (Canada)), Ana-Maria Guerra-Escobio(Xenon Pharmaceuticals (Canada)), Jenni Risler(Xenon Pharmaceuticals (Canada)), Sébastien Meilleur(Xenon Pharmaceuticals (Canada)), Roger Green(Capitol Technology University), Chris Radomski(Xenon Pharmaceuticals (Canada)), William Pryse‐Phillips(Memorial University of Newfoundland), Simon N. Pimstone(Xenon Pharmaceuticals (Canada)), Mary O’Driscoll(Birmingham Women's Hospital), Y. Paul Goldberg(University of British Columbia), Guy A. Rouleau(Montreal Neurological Institute and Hospital), Robin Sherrington(Xenon Pharmaceuticals (Canada)), H. Banfield Younghusband(Memorial University of Newfoundland)
The American Journal of Human Genetics
April 16, 2004
Cited by 157


Related Papers